<p>Data are means ± SEM. The decrease in LDL cholesterol was significant in all groups (all <i>P</i><0.0001), the increase in PCSK9 was significant in the simvastatin and in the combination groups (<i>P</i><0.005), but not in the ezetimibe group.</p
<p>APS and simvastatin significantly lowered total cholesterol (TC), triglycerides (TG), high-densit...
Statins are currently the main group of lipid-lowering drugs used in clinical practice. However not ...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...
<p>Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low...
<p>(A) Correlation between baseline PCSK9 concentrations (log-transformed) and percent change in PCS...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower LDL-...
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-...
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-...
Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...
<p>Plasma concentrations of TC (square), TG (triangle), LDL-C (diamond), and HDL-C (circle) in the p...
<p>APS and simvastatin significantly lowered total cholesterol (TC), triglycerides (TG), high-densit...
Statins are currently the main group of lipid-lowering drugs used in clinical practice. However not ...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...
<p>Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low...
<p>(A) Correlation between baseline PCSK9 concentrations (log-transformed) and percent change in PCS...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower LDL-...
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-...
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-...
Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...
<p>Plasma concentrations of TC (square), TG (triangle), LDL-C (diamond), and HDL-C (circle) in the p...
<p>APS and simvastatin significantly lowered total cholesterol (TC), triglycerides (TG), high-densit...
Statins are currently the main group of lipid-lowering drugs used in clinical practice. However not ...
BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...
DOI
Add to ORKG